Recently, Yunnan Walvax BioThe 23-valent pneumococcal polysaccharide vaccine ( hereinafter referred to as " 23-valent pneumococcal vaccine") produced by Yuxi Walvax Biotechnology Co. , Ltd., a subsidiary of Walvax Biotechnology Co., Ltd. (hereinafter referred to as "Walvax Biotechnology"), has completed its first export delivery to El Salvador. This milestone event marks the first export of Walvax Biotechnology to El Salvador.The product officially entered the Latin American market, further expanding its global layout.

According to data disclosed by Walvax Bio, as the world's first preservative-free 23-valent pneumococcal polysaccharide vaccine, this product is suitable for children over 2 years old and high-risk adults. The cumulative global sales volume has exceeded 14 million doses.

As of now, Walvax Bio has built a diversified global vaccine supply network. Its products, including 13-valent pneumococcal polysaccharide conjugate vaccine, bivalent human papillomavirus vaccine (Pichia pastoris), 23-valent pneumococcal vaccine, ACYW135 group meningococcal polysaccharide vaccine, group A and group C meningococcal polysaccharide vaccine, have been exported to more than 20 countries and regions, with markets covering Southeast Asia, South Asia, the Middle East, Africa, North America and Central America. Public health services cover many countries including Indonesia, the United States, Morocco, Egypt, Thailand, Nigeria, Senegal, etc.

In addition, Walvax Bio also plans to implement an interim dividend. According to the company's disclosed distribution plan, the company will pay a cash dividend of 0.30 yuan (including tax) per 10 shares to all shareholders, with a total cash dividend of 47.9805 million yuan.

https://finance.eastmoney.com/a/202508283498156847.html